Logo image of ZYNE

ZYNERBA PHARMACEUTICALS INC (ZYNE) Stock Fundamental Analysis

NASDAQ:ZYNE - Nasdaq - US98986X1090 - Common Stock - Currency: USD

1.3  +0.03 (+2.36%)

After market: 1.3015 +0 (+0.12%)

Fundamental Rating

2

ZYNE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. ZYNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ZYNE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ZYNE had negative earnings in the past year.
In the past year ZYNE has reported a negative cash flow from operations.
ZYNE had negative earnings in each of the past 5 years.
In the past 5 years ZYNE always reported negative operating cash flow.
ZYNE Yearly Net Income VS EBIT VS OCF VS FCFZYNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -92.85%, ZYNE is doing worse than 78.47% of the companies in the same industry.
Looking at the Return On Equity, with a value of -129.50%, ZYNE is doing worse than 67.94% of the companies in the same industry.
Industry RankSector Rank
ROA -92.85%
ROE -129.5%
ROIC N/A
ROA(3y)-59.46%
ROA(5y)-55.04%
ROE(3y)-71.26%
ROE(5y)-65.33%
ROIC(3y)N/A
ROIC(5y)N/A
ZYNE Yearly ROA, ROE, ROICZYNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80

1.3 Margins

ZYNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYNE Yearly Profit, Operating, Gross MarginsZYNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -50K -100K -150K -200K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for ZYNE has been increased compared to 1 year ago.
ZYNE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZYNE Yearly Shares OutstandingZYNE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ZYNE Yearly Total Debt VS Total AssetsZYNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -8.88, we must say that ZYNE is in the distress zone and has some risk of bankruptcy.
ZYNE has a Altman-Z score of -8.88. This is in the lower half of the industry: ZYNE underperforms 74.64% of its industry peers.
There is no outstanding debt for ZYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.88
ROIC/WACCN/A
WACCN/A
ZYNE Yearly LT Debt VS Equity VS FCFZYNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 3.43 indicates that ZYNE has no problem at all paying its short term obligations.
With a Current ratio value of 3.43, ZYNE perfoms like the industry average, outperforming 49.76% of the companies in the same industry.
ZYNE has a Quick Ratio of 3.43. This indicates that ZYNE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.43, ZYNE is in line with its industry, outperforming 52.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.43
Quick Ratio 3.43
ZYNE Yearly Current Assets VS Current LiabilitesZYNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

ZYNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.98%, which is quite good.
EPS 1Y (TTM)13.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 31.48% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.82%
EPS Next 2Y10.85%
EPS Next 3Y15.71%
EPS Next 5Y31.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYNE Yearly Revenue VS EstimatesZYNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
ZYNE Yearly EPS VS EstimatesZYNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ZYNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZYNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYNE Price Earnings VS Forward Price EarningsZYNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYNE Per share dataZYNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

ZYNE's earnings are expected to grow with 15.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.85%
EPS Next 3Y15.71%

More info and screens

0

5. Dividend

5.1 Amount

ZYNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYNERBA PHARMACEUTICALS INC

NASDAQ:ZYNE (10/10/2023, 8:00:03 PM)

After market: 1.3015 +0 (+0.12%)

1.3

+0.03 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2023-08-14/bmo
Earnings (Next)11-13 2023-11-13/bmo
Inst Owners0.03%
Inst Owner Change0%
Ins Owners2.98%
Ins Owner Change0%
Market Cap70.12M
Analysts48.89
Price Target1.28 (-1.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.52%
Min EPS beat(2)-8.36%
Max EPS beat(2)-4.68%
EPS beat(4)2
Avg EPS beat(4)1.11%
Min EPS beat(4)-8.36%
Max EPS beat(4)12.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-78.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)145%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.91%
Revenue NQ rev (1m)99900%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.42
P/tB 2.42
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.85%
ROE -129.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.46%
ROA(5y)-55.04%
ROE(3y)-71.26%
ROE(5y)-65.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.34%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.43
Quick Ratio 3.43
Altman-Z -8.88
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)101.27%
Cap/Depr(5y)138.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-2.82%
EPS Next 2Y10.85%
EPS Next 3Y15.71%
EPS Next 5Y31.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.8%
EBIT Next 3Y1.94%
EBIT Next 5Y31.42%
FCF growth 1Y9.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.18%
OCF growth 3YN/A
OCF growth 5YN/A